All In MedTech

Company

Neuropace

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

This company is not on our public-company list, so only this exact name is matched. Naming a company here is not a recommendation of it or of any security.

Financing

Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.

Public

Listed

NPCE

Nasdaq · NeuroPace Inc

Public float

$306M

Value of shares held by non-insiders on Jun 30, 2025

Revenue

$100.0M

Fiscal year ending Dec 31, 2025

Net income

-$21.5M

Fiscal year ending Dec 31, 2025

R&D spending

$27.9M

Fiscal year ending Dec 31, 2025

Cash

$10.2M

As of Sep 30, 2026

Long-term debt

$59.2M

As of Sep 30, 2026

Shares outstanding

34.5M

As of Nov 10, 2026

Capital raised as a public company

Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.

YearIPOStock soldLong-term debtConvertible debt
2024$3.3M–––
2023$7.9M–––
2021$109M–––

Private placements (Form D)

One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.

First saleTypeRaisedRound sizeInvestorsExemption and agentFiling
Aug 19, 2020Equity$69.4M$96.4M23Rule 506(b)Form D ↗Aug 31, 2020
Sep 21, 2016Equity$72.0M$80.0M26Rule 506(b)Form D/A ↗Aug 8, 20171 amendment
Jul 1, 2013Equity$18.1M$50.0M20Rule 506Form D ↗Jul 9, 2013

1 more funding rounds with a free account

Company details

From the company's latest Form D.

Legal name
NeuroPace Inc
Headquarters
Mountain View, California
Incorporated
Delaware over five years before filing
Entity type
Corporation
Revenue range
Decline to Disclose
Industry filed under
Other Health Care

Executives, directors and promoters

As listed on the latest Form D.

    10 more people on the filing with a free account

    Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

    Investors

    5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

    The investor database is part of the paid tier

    For Neuropace we have 4 shareholders with 5% or more.

    It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.

    Latest FDA decisions

    Search the Clearance Tracker

    No 510(k), De Novo or PMA decisions under this name since 2015.

    Device trials

    Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

    Open in the Trial Radar
    • NCT07823465 · 100 participants (planned) · Start Sep 14, 2026 · Primary completion Feb 2027

      Device: NeuroPace RNS System · For: Focal Epilepsy; Drug-resistant Focal Epilepsy

      Sites: Waltham, Massachusetts

    • RNS System LGS Feasibility StudyActive, not recruiting

      NCT05339126 · 24 participants (planned) · Start Oct 4, 2022 · Primary completion Nov 30, 2026

      Device: RNS System · For: Epilepsy; Lennox Gastaut Syndrome; Lennox-Gastaut Syndrome, Intractable and 2 more

      Sites: Birmingham, Alabama; San Francisco, California; Atlanta, Georgia · 6 sites in all

    • RNS System NAUTILUS StudyPivotal-lookingCompleted

      NCT05147571 · 100 participants · Start Aug 9, 2022 · Primary completion Apr 4, 2025

      Device: Responsive stimulation; Sham stimulation · For: Epilepsy; Idiopathic Generalized Epilepsy; Generalized Tonic Clonic Seizure

      Sites: Birmingham, Alabama; Phoenix, Arizona; Aurora, Colorado · 23 sites in all

    6 more trials with a free account

    Reports received

    135

    Received Nov 1, 2025 to Nov 20, 2026. Includes 1 of another or unstated type.

    Malfunction reports

    36

    27% of reports

    Injury reports

    95

    70% of reports

    Death reports

    3

    2.2% of reports

    Adverse event reports received per month

    Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

    Search the MAUDE Monitor
    • Malfunction
    • Injury
    • Death
    • Other
    View as table
    MonthMalfunctionInjuryDeathOther
    Dec 230500
    Jan 242700
    Feb 2411200
    Mar 242700
    Apr 240400
    May 242600
    Jun 243200
    Jul 244800
    Aug 242600
    Sep 240000
    Oct 240300
    Nov 242400
    Dec 244400
    Jan 253100
    Feb 251400
    Mar 251800
    Apr 251600
    May 252100
    Jun 253500
    Jul 253600
    Aug 251200
    Sep 253800
    Oct 250400
    Nov 253600
    Dec 2551200
    Jan 2621500
    Feb 262500
    Mar 265710
    Apr 266300
    May 2661000
    Jun 265600
    Jul 262200
    Aug 260701
    Sep 2601410
    Oct 260810
    Nov 260000

    Device types named most often

    Last 12 months, by FDA product code. A company that sells more gets more reports.

    Brand names named most often

    Last 12 months, as written on the reports. One product can appear under several spellings.

    3 more in this ranking with a free account

    Recent recalls

    From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

    No recalls under this name in FDA's data.

    Back to all tools

    For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.